Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency
Main finding · Change in DXA total lean massResult — go to the resultMean difference −0.2 kg 95% CI −1.5 to 1.1Authors' conclusion
In routine practice, switching to once-weekly somapacitan was associated with improved functional outcomes, despite less favorable adiposity trajectories, compared with daily therapy.
Study context
- Population
- Adults with GHD on growth hormone (GH) replacement therapy, single centre, routine endocrine care
- Participants
- 57 adults
- Exposure
- Switch from daily GH to once-weekly somapacitan vs continued daily GH
- Outcome
- DXA-derived change in total lean mass
- Follow-up
- Baseline to week 52
Methodological detailsnonrandomized, single-centre, self-selected by patient preference
- Nonrandomized
- Single-centre
- Self-selected by patient preference
Main finding
Change in DXA total lean mass
Mean difference
−0.2 kg
95% CI −1.5 to 1.1
Switch from daily GH to once-weekly somapacitanvs continued daily GH
mean difference −0.2 kg (95% CI −1.5 to 1.1)
As reported in the abstract
Observational data: associations, not effects.
Further findings
IGF-1 SD scores · baseline and week 52
- Distributions similar between groups; increase greater with daily GH than with somapacitan
Adiposity indices and HDL-C
- Somapacitan associated with increased adiposity indices, yet improved HDL-C
Handgrip strength and Timed Up and Go Test
- Improvements in handgrip strength and Timed Up and Go Test
- Exploratory analyses
Original publication
Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. J Clin Endocrinol Metab. Published 7 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →